Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 205

1.

Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis.

Kuhle J, Malmeström C, Axelsson M, Plattner K, Yaldizli O, Derfuss T, Giovannoni G, Kappos L, Lycke J.

Acta Neurol Scand. 2013 Dec;128(6):e33-6. doi: 10.1111/ane.12151. Epub 2013 Jun 13.

PMID:
23763388
2.

A comparative study of CSF neurofilament light and heavy chain protein in MS.

Kuhle J, Plattner K, Bestwick JP, Lindberg RL, Ramagopalan SV, Norgren N, Nissim A, Malaspina A, Leppert D, Giovannoni G, Kappos L.

Mult Scler. 2013 Oct;19(12):1597-603. doi: 10.1177/1352458513482374. Epub 2013 Mar 25.

PMID:
23529999
3.

The impact of pre-analytical variables on the stability of neurofilament proteins in CSF, determined by a novel validated SinglePlex Luminex assay and ELISA.

Koel-Simmelink MJ, Vennegoor A, Killestein J, Blankenstein MA, Norgren N, Korth C, Teunissen CE.

J Immunol Methods. 2014 Jan 15;402(1-2):43-9. doi: 10.1016/j.jim.2013.11.008. Epub 2013 Nov 22.

PMID:
24275679
4.

Cerebrospinal fluid light and heavy neurofilaments in neuromyelitis optica.

Wang H, Wang C, Qiu W, Lu Z, Hu X, Wang K.

Neurochem Int. 2013 Dec;63(8):805-8. doi: 10.1016/j.neuint.2013.10.008. Epub 2013 Oct 23.

PMID:
24161620
5.

A highly sensitive electrochemiluminescence immunoassay for the neurofilament heavy chain protein.

Kuhle J, Regeniter A, Leppert D, Mehling M, Kappos L, Lindberg RL, Petzold A.

J Neuroimmunol. 2010 Mar 30;220(1-2):114-9. doi: 10.1016/j.jneuroim.2010.01.004. Epub 2010 Feb 1.

PMID:
20117845
6.

Longitudinal one-year study of levels and stoichiometry of neurofilament heavy and light chain concentrations in CSF in patients with multiple system atrophy.

Petzold A, Thompson EJ, Keir G, Quinn N, Holmberg B, Dizdar N, Wenning GK, Rascol O, Tolosa E, Rosengren L.

J Neurol Sci. 2009 Apr 15;279(1-2):76-9. doi: 10.1016/j.jns.2008.12.037. Epub 2009 Feb 4.

PMID:
19195665
7.

Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study.

Petzold A, Eikelenboom MJ, Keir G, Grant D, Lazeron RH, Polman CH, Uitdehaag BM, Thompson EJ, Giovannoni G.

J Neurol Neurosurg Psychiatry. 2005 Feb;76(2):206-11.

8.

Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis.

Teunissen CE, Iacobaeus E, Khademi M, Brundin L, Norgren N, Koel-Simmelink MJ, Schepens M, Bouwman F, Twaalfhoven HA, Blom HJ, Jakobs C, Dijkstra CD.

Neurology. 2009 Apr 14;72(15):1322-9. doi: 10.1212/WNL.0b013e3181a0fe3f.

PMID:
19365053
9.

Multiple sclerosis: Neurofilament light chain antibodies are correlated to cerebral atrophy.

Eikelenboom MJ, Petzold A, Lazeron RH, Silber E, Sharief M, Thompson EJ, Barkhof F, Giovannoni G, Polman CH, Uitdehaag BM.

Neurology. 2003 Jan 28;60(2):219-23.

PMID:
12552034
10.

Serum and cerebrospinal fluid light neurofilaments and antibodies against them in clinically isolated syndrome and multiple sclerosis.

Fialová L, Bartos A, Svarcová J, Zimova D, Kotoucova J, Malbohan I.

J Neuroimmunol. 2013 Sep 15;262(1-2):113-20. doi: 10.1016/j.jneuroim.2013.06.010. Epub 2013 Jul 17.

PMID:
23870535
11.

A systematic review and meta-analysis of CSF neurofilament protein levels as biomarkers in dementia.

Petzold A, Keir G, Warren J, Fox N, Rossor MN.

Neurodegener Dis. 2007;4(2-3):185-94. Review.

PMID:
17596713
12.

Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis.

Lycke JN, Karlsson JE, Andersen O, Rosengren LE.

J Neurol Neurosurg Psychiatry. 1998 Mar;64(3):402-4.

13.

Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis.

Axelsson M, Malmeström C, Nilsson S, Haghighi S, Rosengren L, Lycke J.

J Neurol. 2011 May;258(5):882-8. doi: 10.1007/s00415-010-5863-2. Epub 2011 Jan 1.

PMID:
21197541
14.

CSF neurofilament and N-acetylaspartate related brain changes in clinically isolated syndrome.

Khalil M, Enzinger C, Langkammer C, Ropele S, Mader A, Trentini A, Vane ML, Wallner-Blazek M, Bachmaier G, Archelos JJ, Koel-Simmelink MJ, Blankenstein MA, Fuchs S, Fazekas F, Teunissen CE.

Mult Scler. 2013 Apr;19(4):436-42. doi: 10.1177/1352458512458010. Epub 2012 Aug 23.

15.

Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa.

Kuhle J, Barro C, Andreasson U, Derfuss T, Lindberg R, Sandelius Å, Liman V, Norgren N, Blennow K, Zetterberg H.

Clin Chem Lab Med. 2016 Oct 1;54(10):1655-61. doi: 10.1515/cclm-2015-1195.

PMID:
27071153
16.

Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis.

Axelsson M, Malmeström C, Gunnarsson M, Zetterberg H, Sundström P, Lycke J, Svenningsson A.

Mult Scler. 2014 Jan;20(1):43-50. doi: 10.1177/1352458513490544. Epub 2013 May 23.

PMID:
23702432
17.

Neurofilament light antibodies in serum reflect response to natalizumab treatment in multiple sclerosis.

Amor S, van der Star BJ, Bosca I, Raffel J, Gnanapavan S, Watchorn J, Kuhle J, Giovannoni G, Baker D, Malaspina A, Puentes F.

Mult Scler. 2014 Sep;20(10):1355-62. doi: 10.1177/1352458514521887. Epub 2014 Feb 10.

PMID:
24515731
18.

Cerebrospinal fluid immunological biomarkers associated with axonal damage in multiple sclerosis.

Villar LM, Picón C, Costa-Frossard L, Alenda R, García-Caldentey J, Espiño M, Muriel A, Álvarez-Cermeño JC.

Eur J Neurol. 2015 Aug;22(8):1169-75. doi: 10.1111/ene.12579. Epub 2014 Oct 17.

PMID:
25324032
19.

Assessing tissue damage in multiple sclerosis: a biomarker approach.

Burman J, Zetterberg H, Fransson M, Loskog AS, Raininko R, Fagius J.

Acta Neurol Scand. 2014 Aug;130(2):81-9. doi: 10.1111/ane.12239. Epub 2014 Feb 24.

PMID:
24571714
20.

Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis.

Kuhle J, Leppert D, Petzold A, Regeniter A, Schindler C, Mehling M, Anthony DC, Kappos L, Lindberg RL.

Neurology. 2011 Apr 5;76(14):1206-13. doi: 10.1212/WNL.0b013e31821432ff. Epub 2011 Feb 23.

PMID:
21346223

Supplemental Content

Support Center